Eli Lilly raises 2026 revenue forecast as GLP-1 drugs fuel growth
Eli Lilly lifted its full-year revenue guidance on strong GLP-1 sales, which the company cited as the driver of sustained growth.
Reuters · +14 outlets
Novo Nordisk lifts 2026 outlook but Wegovy pill sales disappoint
Novo raised its 2026 forecast yet shares dipped as oral Wegovy and CagriSema results failed to impress investors.
Reuters · +14 outlets
Eli Lilly to offer early access to experimental obesity drug retatrutide
Lilly will let more patients apply for special access to its unapproved next-gen obesity drug retatrutide under a narrow early-access program.
Reuters · +14 outlets
Pfizer halts oral obesity drug MET-224o trial from D&D Pharmatech, cites strategy
Pfizer ended its trial of the ex-Metsera oral obesity asset MET-224o, attributing the halt to strategic priorities rather than technology issues, and D&D Pharma
Fierce Biotech · +3 outlets
Pfizer beats earnings estimates, targets $2.5B in additional cost cuts
Pfizer topped Q2 earnings expectations and raised its 2026 revenue guidance midpoint while announcing $2.5 billion in fresh cost reductions.
ET Pharma · +5 outlets
FDA approves first PROTAC therapy as Arvinas licenses VEPPANU
The FDA approved the first PROTAC-class therapy, with Arvinas licensing the product VEPPANU, a milestone for targeted protein degradation.
Stock Titan · +6 outlets
Obesity battle heats up again as Novo claws back into race with Lilly
Novo is reasserting itself in the obesity market against Eli Lilly as GLP-1 competition intensifies on both earnings and pipeline fronts.
Reuters · +7 outlets
FDA approves Merck's once-daily oral drug LIPFENDRA to reduce LDL-C
The FDA cleared Merck's once-daily oral cholesterol-lowering drug LIPFENDRA, which contributed to its revenue beat even as Terns acquisition costs cratered prof
Stock Titan · +14 outlets
Exempting rare disease therapies from drug-pricing pilots would wipe out savings, analysis finds
A STAT analysis finds that exempting orphan drugs from Trump administration drug-pricing pilots would erase the bulk of projected savings.
STAT · +1 outlets
FDA approval expands CASGEVY to children as young as 2
The FDA expanded approval of Vertex and CRISPR's sickle cell gene therapy CASGEVY to children as young as two years old.
Stock Titan · +14 outlets
Senators back bill to reform drug pricing program
A bipartisan group of senators is backing legislation to reform the federal drug pricing program.
Punchbowl News · +14 outlets
FDA approval for Novartis' Pluvicto nearly doubles eligible patient pool
An expanded FDA approval for Novartis' radioligand therapy Pluvicto roughly doubles the number of eligible patients.
Benzinga · +8 outlets
Sandoz floats nearly $500M to resolve US generic drug antitrust claims
Sandoz proposed paying close to $500 million to settle the bulk of lingering US antitrust claims over generic drug price fixing.
Fierce Pharma · +1 outlets
CORT stock soars 35% after early FDA nod for ovarian cancer drug
Corcept Therapeutics shares jumped 35% after an early FDA approval for its ovarian cancer drug.
Stocktwits
CAPR stock on track for worst day ever as analysts split on deramiocel approval odds
Capricor shares fell sharply after FDA documents raised concerns about deramiocel's approval probability, dividing analysts.
Stocktwits · +2 outlets
Amgen results show biosimilars, IRA pricing reshaping drug spend
Amgen's latest results illustrate how biosimilar competition and IRA pricing provisions are reshaping pharmaceutical spending.
Insurance Business
FDA approves Afrezza to treat diabetes in children, MNKD stock jumps
The FDA approved MannKind's inhaled insulin Afrezza for use in children with diabetes, sending shares higher.
Stocktwits · +4 outlets
Rocket Pharmaceuticals touts positive early safety data from revised gene therapy trial
Rocket Pharmaceuticals reported positive early safety data from its revised genetic therapy trial.
Benzinga · +4 outlets